List of Excipients in Branded Drug METOPROLOL SUCCINATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lannett Company Inc	METOPROLOL SUCCINATE	metoprolol succinate	0527-2600	HYPROMELLOSE
Lannett Company Inc	METOPROLOL SUCCINATE	metoprolol succinate	0527-2600	PARAFFIN
Lannett Company Inc	METOPROLOL SUCCINATE	metoprolol succinate	0527-2600	POLYETHYLENE GLYCOL
Lannett Company Inc	METOPROLOL SUCCINATE	metoprolol succinate	0527-2600	SILICON DIOXIDE
Lannett Company Inc	METOPROLOL SUCCINATE	metoprolol succinate	0527-2600	SODIUM STEARYL FUMARATE
Lannett Company Inc	METOPROLOL SUCCINATE	metoprolol succinate	0527-2600	TITANIUM DIOXIDE
NCS HealthCare of KY Inc dba Vangard Labs	METOPROLOL SUCCINATE	metoprolol succinate	0615-8024	HYPROMELLOSES

Generic Drugs Containing METOPROLOL SUCCINATE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	metoprolol succinate	0378-4595	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	metoprolol succinate	0378-4595	ETHYLCELLULOSE
Mylan Pharmaceuticals Inc	metoprolol succinate	0378-4595	HYPROMELLOSE
Mylan Pharmaceuticals Inc	metoprolol succinate	0378-4595	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	metoprolol succinate	0378-4595	POLYETHYLENE GLYCOL
Mylan Pharmaceuticals Inc	metoprolol succinate	0378-4595	SILICON DIOXIDE
Mylan Pharmaceuticals Inc	metoprolol succinate	0378-4595	SODIUM STEARYL FUMARATE

What are the Most Frequently-Used Excipients in METOPROLOL SUCCINATE?

# Of NDCs	Excipient
114	ACETYLTRIBUTYL CITRATE
12	ALCOHOL
3	CALCIUM STEARATE
5	CAPRYLIC/CAPRIC/LAURIC TRIGLYCERIDE
3	CARBOXYMETHYLCELLULOSE SODIUM
22	CARNAUBA WAX
275	CELLULOSE, MICROCRYSTALLINE

Excipient Strategy and Commercial Opportunities for Metoprolol Succinate

Last updated: February 26, 2026

What are primary excipient components in Metoprolol Succinate formulations?

Metoprolol succinate is a sustained-release beta-blocker used for hypertension and heart failure. Its formulations typically involve excipients that control drug release, stability, and manufacturability.

Common excipients include:

• Hydroxypropyl methylcellulose (HPMC): Used as a matrixFormer for extended-release profiles.
• Polyethylene glycol (PEG): Acts as a plasticizer and stabilizer.
• Lactose monohydrate: Filler and carrier.
• Magnesium stearate: Lubricant facilitating tablet compression.
• Silicon dioxide: Anti-caking agent.

In particular, HPMC is critical for controlling the drug's release profile by forming a gel matrix, ensuring sustained delivery over 12–24 hours akin to core-release formulations.

How does excipient selection influence manufacturing and regulation?

Excipient choice impacts processability, bioavailability, and regulatory approval pathways.

• Processability: Compatibility with standard tablet presses or encapsulation techniques. Hydrophilic polymers like HPMC exhibit predictable swelling and erosion behaviors.
• Bioavailability: Excipients such as lactose and PEG influence dissolution rates, affecting absorption.
• Regulatory: Excipients like lactose may be limited due to allergen considerations, especially in populations with lactose intolerance. Drug regulators require excipient manufacturing and sourcing to meet strict pharmacopeial standards.

What are the commercial implications of excipient strategy?

Optimizing excipients offers multiple benefits:

Cost efficiencies

• Using bulk, readily available excipients like HPMC and lactose reduces production costs.
• Developing generic versions with interchangeable excipients broadens market access.

Market differentiation

• Innovating excipient blends that improve stability or release profiles can distinguish products.
• Novel combinations can permit proprietary sustained-release mechanisms and extend patent protection.

Regulatory advantages

• Using excipients with well-documented safety profiles simplifies approval.
• Changes in excipient sources or formulations require supplemental filings.

Supply chain considerations

• Relying on globally sourced excipients minimizes supply risks.
• Diversifying excipient suppliers mitigates shortages and enhances production resilience.

Consumer considerations

• Excipients like lactose may limit patient usability; alternatives such as microcrystalline cellulose can improve tolerability.

What are current market trends and opportunities?

Growing demand for sustained-release formulations

The shift toward once-daily dosing enhances patient adherence. Excipient innovation enables these formulations, creating opportunities for companies to develop proprietary extended-release versions.

Expansion into emerging markets

Cost-effective excipient combinations align with price-sensitive markets. Local manufacturing of excipients can lower costs and facilitate regulatory approval.

Personalized medicine

Tailoring excipient content for specific populations (e.g., lactose-free formulations for lactose-intolerant patients) expands market reach.

Patent landscape

Excipients used in innovative matrices can support patent filings, extending market exclusivity on formulations.

Regulatory evolution

Global agencies are updating excipient safety standards, encouraging R&D into novel excipients that can enable faster approval timelines.

What development strategies could enhance commercial prospects?

• Formulation innovation: Incorporate bio-available and tolerability-improving excipients.
• Supply chain strength: Secure multiple sources for key excipients to prevent bottlenecks.
• Regulatory engagement: Early interaction with regulators to define acceptable excipient profiles and documentation.
• Partnerships: Collaborate with excipient manufacturers to co-develop proprietary blends.

---

Key Takeaways

• Excipients in metoprolol succinate formulations primarily include HPMC, lactose, PEG, and magnesium stearate.
• Excipient selection affects manufacturing, regulatory pathways, and marketability.
• Innovations in excipient formulations can improve drug stability, extend patent life, and support differentiated products.
• Cost, supply chain stability, patient tolerability, and regulatory compliance are critical factors influencing commercial strategy.
• Growing demand for sustained-release and personalized options presents expansion opportunities.

---

Frequently Asked Questions

1. What excipients are preferred for extended-release metoprolol formulations?
Hydroxypropyl methylcellulose (HPMC) is the preferred matrix-forming polymer due to its gel-forming properties that enable controlled drug release.

2. How does excipient choice impact patent protection?
Innovative excipient combinations or novel matrices can support formulation patents, delaying generic competition and extending market exclusivity.

3. Are there regulatory concerns associated with excipient changes?
Yes. Changes require regulatory notifications or approvals, especially if excipients are sourced from different suppliers or if their grades differ.

4. Can alternative excipients improve patient tolerability?
Yes. For example, substituting lactose with microcrystalline cellulose can benefit lactose-sensitive patients.

5. What supply chain risks are associated with excipients?
Global shortages, quality variability, and geopolitical factors can disrupt supply. Diversifying suppliers mitigates these risks.

---

References

[1] U.S. Food and Drug Administration. (2020). Guidance for industry: Excipients in pharmaceutical products.
[2] European Medicines Agency. (2019). Guideline on excipients in the label and package leaflet of medicinal products.
[3] Chien, Y. W. (2016). Biopharmaceutics and Pharmacokinetics.
[4] Martindale: The Complete Drug Reference. (2020). Excipients in drug formulations.